These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 33110232)

  • 1. Sox2 is necessary for androgen ablation-induced neuroendocrine differentiation from Pten null Sca-1
    Kwon OJ; Zhang L; Jia D; Xin L
    Oncogene; 2021 Jan; 40(1):203-214. PubMed ID: 33110232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumours.
    Sackmann Sala L; Boutillon F; Menara G; De Goyon-Pélard A; Leprévost M; Codzamanian J; Lister N; Pencik J; Clark A; Cagnard N; Bole-Feysot C; Moriggl R; Risbridger GP; Taylor RA; Kenner L; Guidotti JE; Goffin V
    J Pathol; 2017 Sep; 243(1):51-64. PubMed ID: 28603917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Castration-Resistant Bmi1+Sox2+ Cells in Driving Recurrence in Prostate Cancer.
    Yoo YA; Vatapalli R; Lysy B; Mok H; Desouki MM; Abdulkadir SA
    J Natl Cancer Inst; 2019 Mar; 111(3):311-321. PubMed ID: 30312426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Sca-1
    Kwon OJ; Choi JM; Zhang L; Jia D; Li Z; Zhang Y; Jung SY; Creighton CJ; Xin L
    Stem Cells; 2020 Nov; 38(11):1479-1491. PubMed ID: 32627901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer.
    Brennen WN; Zhu Y; Coleman IM; Dalrymple SL; Antony L; Patel RA; Hanratty B; Chikarmane R; Meeker AK; Zheng SL; Hooper JE; Luo J; De Marzo AM; Corey E; Xu J; Yegnasubramanian S; Haffner MC; Nelson PS; Nelson WG; Isaacs WB; Isaacs JT
    JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33724955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sox2 Expression Marks Castration-Resistant Progenitor Cells in the Adult Murine Prostate.
    McAuley E; Moline D; VanOpstall C; Lamperis S; Brown R; Vander Griend DJ
    Stem Cells; 2019 May; 37(5):690-700. PubMed ID: 30720908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer.
    Zou M; Toivanen R; Mitrofanova A; Floch N; Hayati S; Sun Y; Le Magnen C; Chester D; Mostaghel EA; Califano A; Rubin MA; Shen MM; Abate-Shen C
    Cancer Discov; 2017 Jul; 7(7):736-749. PubMed ID: 28411207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
    Kaur H; Samarska I; Lu J; Faisal F; Maughan BL; Murali S; Asrani K; Alshalalfa M; Antonarakis ES; Epstein JI; Joshu CE; Schaeffer EM; Mosquera JM; Lotan TL
    Prostate; 2020 Sep; 80(12):1012-1023. PubMed ID: 32649013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer.
    Kregel S; Kiriluk KJ; Rosen AM; Cai Y; Reyes EE; Otto KB; Tom W; Paner GP; Szmulewitz RZ; Vander Griend DJ
    PLoS One; 2013; 8(1):e53701. PubMed ID: 23326489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-androgen therapy induces transcriptomic reprogramming in metastatic castration-resistant prostate cancer in a murine model.
    Zhao Y; Peng X; Baldwin H; Zhang C; Liu Z; Lu X
    Biochim Biophys Acta Mol Basis Dis; 2021 Jul; 1867(7):166151. PubMed ID: 33892077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in a PTEN-deficient mouse model of prostate cancer.
    De Velasco MA; Tanaka M; Yamamoto Y; Hatanaka Y; Koike H; Nishio K; Yoshikawa K; Uemura H
    Carcinogenesis; 2014 Sep; 35(9):2142-53. PubMed ID: 24986896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SOX2 mediates metabolic reprogramming of prostate cancer cells.
    de Wet L; Williams A; Gillard M; Kregel S; Lamperis S; Gutgesell LC; Vellky JE; Brown R; Conger K; Paner GP; Wang H; Platz EA; De Marzo AM; Mu P; Coloff JL; Szmulewitz RZ; Vander Griend DJ
    Oncogene; 2022 Feb; 41(8):1190-1202. PubMed ID: 35067686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
    Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.
    Hubbard GK; Mutton LN; Khalili M; McMullin RP; Hicks JL; Bianchi-Frias D; Horn LA; Kulac I; Moubarek MS; Nelson PS; Yegnasubramanian S; De Marzo AM; Bieberich CJ
    Cancer Res; 2016 Jan; 76(2):283-92. PubMed ID: 26554830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance.
    Ku SY; Rosario S; Wang Y; Mu P; Seshadri M; Goodrich ZW; Goodrich MM; Labbé DP; Gomez EC; Wang J; Long HW; Xu B; Brown M; Loda M; Sawyers CL; Ellis L; Goodrich DW
    Science; 2017 Jan; 355(6320):78-83. PubMed ID: 28059767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conditionally ablated Pten in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice.
    Lu TL; Huang YF; You LR; Chao NC; Su FY; Chang JL; Chen CM
    Am J Pathol; 2013 Mar; 182(3):975-91. PubMed ID: 23313138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transient Sox9 Expression Facilitates Resistance to Androgen-Targeted Therapy in Prostate Cancer.
    Nouri M; Massah S; Caradec J; Lubik AA; Li N; Truong S; Lee AR; Fazli L; Ramnarine VR; Lovnicki JM; Moore J; Wang M; Foo J; Gleave ME; Hollier BG; Nelson C; Collins C; Dong X; Buttyan R
    Clin Cancer Res; 2020 Apr; 26(7):1678-1689. PubMed ID: 31919137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dependence of castration-resistant prostate cancer (CRPC) stem cells on CRPC-associated fibroblasts.
    Adisetiyo H; Liang M; Liao CP; Jeong JH; Cohen MB; Roy-Burman P; Frenkel B
    J Cell Physiol; 2014 Sep; 229(9):1170-6. PubMed ID: 24752784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-renewing Pten-/- TP53-/- protospheres produce metastatic adenocarcinoma cell lines with multipotent progenitor activity.
    Abou-Kheir W; Hynes PG; Martin P; Yin JJ; Liu YN; Seng V; Lake R; Spurrier J; Kelly K
    PLoS One; 2011; 6(10):e26112. PubMed ID: 22022528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TUBB3 is associated with PTEN, neuroendocrine differentiation, and castration resistance in prostate cancer.
    Sekino Y; Han X; Babasaki T; Miyamoto S; Kobatake K; Kitano H; Ikeda K; Goto K; Inoue S; Hayashi T; Teishima J; Shiota M; Takeshima Y; Yasui W; Matsubara A
    Urol Oncol; 2021 Jun; 39(6):368.e1-368.e9. PubMed ID: 33771409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.